S'abonner

Initial evaluation of cervical cancer: A literature review of staging conization for accurate risk stratification and guidance of primary treatment in early-stage disease - A review from the French cervical cancer guidelines group - 26/09/26

Doi : 10.1016/j.jogoh.2026.103274 
Walid Chlala a, Amélia Favier b, c, Xavier Carcopino d, Geoffroy Canlorbe b, e, f, Claire Sanson a, ⁎

the members from the FRENCH CERVICAL CANCER GUIDELINES GROUP 1

  Authors from the FRENCH CERVICAL CANCER GUIDELINES GROUP: Xavier Carcopino 1,* , Lobna Ouldamer 2 , Cyrille Huchon 3 , Pauline Asseeva 4 , Henri Azaïs 5 , Sofiane Bendifallah 6 , Jean-Luc Brun 7 , Geoffroy Canlorbe 8 , Cyrus Chargari 9 , Pauline Chauvet 10 , Abel Cordoba 11 , Hélène Courcier 12 , Yohann Dabi 13 , Marion de Berti 2 , Caroline Diguisto 2 , Eva Fuss 14 , Thomas Gaillard 15 Tristan Gauthier 16 , Witold Gertych 17 , Laurence Gladieff 18 , Olivier Graesslin 19 , Yohan Kerbage 20 , Martin Koskas 12 , Enora Laas 15 , Aymeline Lacorre 16 , Vincent Lavoué 21 , Lise Lecointre 14 , Fabrice Lecuru 22 , François Margueritte 16 , Alejandra Martinez 23 , PaulJean Maternowski 7 , Patrice Mathevet 24 , Imane Menouer 19 , Camille Mimoun 3 , Anthony Moureau 21 , Antoine Netter 1 , Charles-André Philip 25 , Pascal Rousset 26 , Claire Sanson 27 , Isabelle Thomassin-Naggara 28 , Cyril Touboul 13 , Jean Levêque 21 Affiliations: 1 Department of Obstetrics and Gynaecology, Hôpital Nord, Assistance Publique–Hôpitaux de Marseille (APHM), CEReSS, Center for Studies and Research on Health Services and Quality of Life, Aix Marseille University (AMU), Marseille, France; 2 Department of Gynecology , Centre Hospitalier Universitaire de Tours, INSERM U 1069 ; Université François-Rabelais, Tours, France,; 3 Department of Obstetrics and Gynaecology, Lariboisière Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris Cité University, Paris, France; 4 Department of Nuclear Medicine, Hôpital Nord, Assistance Publique–Hôpitaux de Marseille (APHM), Marseille, France; 5 Department of Gynecologic and Breast Cancer Surgery, Hôpital Européen Georges Pompidou, AP-HP, Paris Cité University, Paris, France; 6 Department of Gynaecologic Surgery, American Hospital of Paris, Neuilly-sur-Seine, France; 7 Department of Gynaecologic Surgery and Reproductive Medicine, Aliénor d’Aquitaine Center, Pellegrin Hospital, Bordeaux, France; 8 Department of Gynaecologic and Breast Cancer Surgery, Pitié-Salpêtrière Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP), Sorbonne University, Saint-Antoine Research Center (CRSA), INSERM UMR_S_ 938 , Cancer Biology and Therapeutics, Paris, France; 9 Department of Radiation Oncology, Pitié-Salpêtrière Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France; 10 Department of Obstetrics and Gynaecology, Estaing University Hospital, Clermont Auvergne University, EnCoV, Institut Pascal, CNRS UMR 6602 , SIGMA Clermont, Clermont-Ferrand, France; 11 Department of Radiation Therapy, Centre Oscar Lambret, Lille, France; 12 Department of Obstetrics and Gynaecology, Bichat Hospital, Paris Cité University, Paris, France; 13 Department of Obstetrics and Gynaecology and Reproductive Medicine, Tenon Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France; 14 Department of Gynaecologic Surgery, Hautepierre University Hospital, Strasbourg, France; 15 Department of Gynaecologic, Breast and Reconstructive Surgery, Institut Curie, Paris, France; 16 Department of Obstetrics and Gynaecology, Women, Mothers and Children Hospital (HFME), Limoges University Hospital, Limoges, France; 17 Department of Gynaecologic and Oncologic Surgery, Lyon Sud Hospital, Lyon, France; 18 Department of Medical Oncology, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, France; 19 Alix de Champagne Mother and Child Institute, Reims University Hospital, University of Reims Champagne-Ardenne (URCA), Reims, France; 20 Department of Gynaecologic Surgery, Lille University Hospital, University of Lille, INSERM U 1189 , OncoThAI: Laser-Assisted Therapies and Immunotherapies for Oncology, Lille, France; 21 Department of Gynaecology, Obstetrics and Human Reproduction, CHU Anne de Bretagne, Faculty of Medicine, University of Rennes, IRSET, INSERM U 1085 , Rennes, France; 22 Department of Breast, Gynaecologic and Reconstructive Surgery, Institut Curie, Faculty of Medicine, Paris Cité University, Paris, France; 23 Oncopole Claudius Regaud, Toulouse University Cancer Institute-Oncopole, Toulouse III–Paul Sabatier University, INSERM, CNRS, University of Toulouse, Toulouse Cancer Research Center, UMR 1037 , Toulouse, France; 24 Lausanne University Hospital (CHUV), Lausanne, Switzerland; University of Lausanne (UNIL), Lausanne, Switzerland; 25 Women and Children Hospital, Hospices Civils de Lyon (HCL), LabTAU INSERM U 1032 , Claude Bernard Lyon 1 University, Lyon, France; 26 Department of Medical and Interventional Imaging, Lyon Sud University Hospital, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, EA CICLY, Lyon, France; 27 Department of Gynaecologic Surgery, Paris Saint-Joseph Hospital Group, Paris, France; 28 Department of Medical Imaging, Tenon Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France.

a Department of Gynecological and Breast Surgery and Oncology, Groupe Hospitalier Paris Saint Joseph, Paris, France 
b Assistance Publique des Hôpitaux de Paris (AP-HP), Department of Gynecological and Breast Surgery and Oncology, Pitié-Salpêtrière University Hospital, Paris, France 
c Sorbonne Université, Inserm, UMR 938, Centre de Recherche Saint Antoine, Equipe Instabilité des Microsatellites et Cancer, Paris, France 
d Department of Obstetrics and Gynaecology, Hôpital Nord, Assistance Publique–Hôpitaux de Marseille (APHM), CEReSS, Center for Studies and Research on Health Services and Quality of Life, Aix Marseille University (AMU), Marseille, France 
e University Institute of Cancer (IUC), AP-HP, Sorbonne University, Paris, France 
f Sorbonne University, Saint-Antoine Research Center (CRSA), INSERM UMR_S_938, Biology and Therapeutics of Cancer, Paris, France 

⁎ Corresponding author at: University Institute of Cancer (IUC), AP-HP, Saint-Antoine Research Center (CRSA), INSERM UMR_S_938, Biology and Therapeutics of Cancer, Paris, France. University Institute of Cancer (IUC), AP-HP, Saint-Antoine Research Center (CRSA), INSERM UMR_S_938, Biology and Therapeutics of Cancer Paris France

Abstract

Prognosis and treatment decisions in early-stage cervical cancer depend on tumor size, depth of stromal invasion, margin status, and lymphovascular space invasion (LVSI). Although pelvic MRI is central to preoperative assessment, imaging may underestimate microscopic invasion or occult residual disease and cannot reliably assess LVSI. This narrative review summarizes evidence on diagnostic or staging conization in early-stage cervical cancer. A literature search was conducted in PubMed/MEDLINE, Embase, and the Cochrane Library, using terms related to cervical cancer, conization, FIGO staging, LVSI, residual disease, parametrial and nodal involvement, recurrence, and survival. Original studies, cohort studies, case-control studies, meta-analyses, and relevant reviews published in English or French were considered, and results were synthesized qualitatively. Conization provides direct histopathological assessment of tumor size, depth of stromal invasion, margin status, and LVSI, thereby improving FIGO staging and preoperative risk stratification. Available studies suggest that conization may predict residual disease and identify high-risk pathological features, including parametrial and lymph node involvement. LVSI detected on the cone specimen is consistently associated with higher risks of parametrial invasion, nodal metastasis, poorer recurrence-free survival, and, in some studies, reduced overall survival. Beyond its diagnostic value, preoperative conization may have a therapeutic impact. Retrospective studies suggest that conization before radical hysterectomy may be associated with a reduced risk of recurrence, particularly in patients undergoing minimally invasive surgery, whereas its impact on overall survival remains uncertain.Overall, staging conization may refine preoperative assessment, guide risk-adapted treatment, and potentially improve recurrence-related outcomes. Prospective studies are needed to clarify its oncological impact.

Le texte complet de cet article est disponible en PDF.

Keywords : Early-stage cervical cancer, Staging conization, Lymphovascular space invasion (LVSI), Parametrial involvement, Lymph node metastasis, recurrence-free survival (RFS)


Plan


© 2026  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 55 - N° 9

Article 103274- novembre 2026 Retour au numéro
Article précédent Article précédent
  • Surgical nodal staging in cervical cancer, a narrative review from the French cervical cancer guidelines group
  • Yohann Dabi, Alejandra Martinez, Aymeline Lacorre, Cyril Touboul, Thomas Gaillard, Vincent Lavoué, Enora Laas, Henri Azaïs, the members from the FRENCH CERVICAL CANCER GUIDELINES GROUP
| Article suivant Article suivant
  • The effect of active cigarette smoking on reproductive outcomes in women undergoing assisted reproductive technology (ART): A systematic review and meta-analysis
  • Iana Malasevskaia, Delvy Rebellow, Roopa Chalasani, Alousious Kasagga, Damilare Michael Akintunde, Nipa Islaml, Puneet Jindal, Ashwin Hassan Gopala, Maryam Afzal, Anushka Verma, Simret Asfaw, Pakeeza Tarar, Anoud Alkaabi, Isha Chopra

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.